Kymera Therapeutics Inc（KYMR）の財務KYMRKymera Therapeutics Inc

Evaluating the bottom line, Kymera Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -116.32%, while the net margin is -94.17%. These profitability ratios, combined with a Return on Equity (ROE) of -24.15%, provide a clear picture of how effectively KYMR converts its operational activities into shareholder value.

In the context of the broader market, KYMR competes directly with industry leaders such as APGE and TWST. With a market capitalization of $9.82B, it holds a leading position in the sector. When comparing efficiency, KYMR's gross margin of 100.00% stands against APGE's N/A and TWST's 52.76%. Such benchmarking helps identify whether Kymera Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Kymera's total revenue for Q2 2026 was $65 million, driven by collaboration revenue, including a $45 million option exercise fee from Gilead and a $20 million milestone payment from Sanofi. Despite the losses, the company has shown improved revenue generation and strong cash reserves of $1.5 billion, which can support future growth.